|

Multiple Sclerosis Clinical Trials in Maryland

33 recruiting studies across 1 city

Browse by City

Baltimore
33 trials

All Trials in Maryland

Phase
Trial Phase Dist.
Confirmatory Trial for Alleviating Fatigue in Multiple SclerosisN/A<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—<1 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/2<1 mi
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisPhase 2<1 mi
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral SclerosisPhase 1<1 mi
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisPhase 4<1 mi
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot StudyN/A<1 mi
Solriamfetol for the Treatment of Multiple Sclerosis FatiguePhase 2<1 mi
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple SclerosisN/A<1 mi
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsPhase 2<1 mi
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Phase 2<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 28 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 39 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 326 mi
TSC Biosample Repository and Natural History Database—30 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 334 mi
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis PlaquesPhase 234 mi
Study of Skin Tumors in Tuberous Sclerosis—34 mi
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)—34 mi
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal LeukoencephalopathyPhase 134 mi
Pathological Basis of MRI Signal Changes in Multiple Sclerosis—34 mi
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring—34 mi
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System—34 mi
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Phase 1/234 mi
Genes and Environment in Multiple Sclerosis—34 mi
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)—34 mi
Study of the Disease Process of Lymphangioleiomyomatosis—34 mi
Role of Genetic Factors in the Development of Lung Disease—34 mi
AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPhase 136 mi
An Open-label Study of AZD0120 in Adults With Multiple SclerosisPhase 136 mi
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPhase 436 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.